# The Safety, Tolerability and Pharmacokinetic Study of Litapiprant Tablets in Healthy Male and Female Subjects

> **NCT03663686** · PHASE1 · COMPLETED · sponsor: **Sunshine Lake Pharma Co., Ltd.** · enrollment: 60 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Litapiprant Tablet

## Key facts

- **NCT ID:** NCT03663686
- **Lead sponsor:** Sunshine Lake Pharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-25
- **Primary completion:** 2019-01-30
- **Final completion:** 2019-01-30
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03663686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03663686, "The Safety, Tolerability and Pharmacokinetic Study of Litapiprant Tablets in Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03663686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*